|
KMID : 1141720210090020064
|
|
폐쇄성폐질환
2021 Volume.9 No. 2 p.64 ~ p.68
|
|
|
COPD and Cardiovascular Disease
|
|
Jung Ji-Ye
|
|
|
Abstract
|
|
|
|
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently occur together and their coexistence is associated with worse outcomes than either condition alone. They share common risk factors, pathophysiological processes, signs and symptoms, and act synergistically as negative prognostic factors. Any bronchodilator is potentially pro-arrhythmic. Although some studies report an incidence of tachydysrythmias in LAMA treated COPD patients, the several trials did not show an increased incidence of major cardiac events. The cardiovascular safety of LABA, LAMA, ICS/LABA, or LABA/LAMA therapy is well established. Angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), and beta-blockers (BB)s are the most commonly prescribed cardiovascular drugs in patients with CVD. Some CVD medications may have a beneficial impact on COPD outcomes, but there have been concerns about β-blocker use leading to bronchospasm in COPD. Off-loading of the CV system through reductions in lung hyperinflation, anti-inflammatory effects and the prevention of exacerbations may help to reduce the risk of CVD.
|
|
|
KEYWORD
|
|
|
Chronic obstructive pulmonary disease, Cardiovascular disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|